Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company’s alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June 8-11, 2024, in Toronto Canada.
- SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company’s alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June 8-11, 2024, in Toronto Canada.
- This clinical trial aims to establish the recommended phase 2 dose and overall therapeutic potential of [212Pb]VMT-α-NET.
- In conjunction with the Phase 0 imaging study as discussed below, this clinical trial will inform the recommended Phase 2 dose of [212Pb]VMT-α-NET.
- The results suggest that imaging with [203Pb]VMT-α-NET at 4 hours post-injection has the best overall diagnostic performance, followed closely by imaging at 1 hour.